dc.date.accessioned2022-01-18T19:34:35Z
dc.date.available2022-01-18T19:34:35Z
dc.date.created2022-01-18T19:34:35Z
dc.date.issued2012
dc.identifierhttps://hdl.handle.net/20.500.12866/11032
dc.identifierhttps://doi.org/10.1179/2047773212Y.0000000046
dc.description.abstractNeurological disease resulting from neurocysticercosis (NCC) is common in most of the world. The variability in the biology of the infection and in its clinical manifestations has led to much confusion regarding appropriate management. Therapeutic options have evolved from surgery, symptomatic measures, and steroids, to include the use of anti-parasitic drugs and minimally invasive neurosurgery. This manuscript reviews the principles of medical therapy for NCC, from discussion of the need for individualized management approaches for each type of NCC to exploration of the most likely potential additions or modifications currently under study.
dc.languageeng
dc.publisherTaylor and Francis
dc.relationPathogens and Global Health
dc.relation2047-7732
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectPeru
dc.subjectnuclear magnetic resonance imaging
dc.subjectmorbidity
dc.subjectmortality
dc.subjectantiparasitic agent
dc.subjectalbendazole
dc.subjectTaenia solium
dc.subjectAnthelmintics
dc.subjectbrain cyst
dc.subjectCysticercosis
dc.subjectoxfendazole
dc.subjectNeurocysticercosis
dc.subjectcarbamazepine
dc.subjectphenytoin
dc.subjectanticonvulsive agent
dc.subjectseizure
dc.subjectNeurosurgical Procedures
dc.titleCurrent status and future perspectives on the medical treatment of neurocysticercosis
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución